抗イディオタイプ抗体は,ヒト腫瘍抗原の内部イメージを担っています
まとめ
人間の胃がん抗原を模倣した抗イディオタイプ抗体 (Ab2) は,元の抗体 (Ab1) と同一の結合特性を持つ抗イディオタイプ抗体 (Ab3) の形成を誘導した. これは,がん免疫療法におけるAb2の可能性を示唆しています.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- バイオテクノロジー バイオテクノロジー
背景:
- 腫瘍抗原を標的とするモノクローナル抗体 (mAbs) は,がん研究において極めて重要です.
- 反イディオタイプ抗体 (Ab2) は,抗原または抗体のエピトープを模倣することができます.
- Ab2誘発の免疫反応を理解することは,新しいがん治療法の開発の鍵です.
研究 の 目的:
- 抗イディオタイプ抗体 (Ab2) を用いて,抗イディオタイプ抗体の生成と特性 (Ab3) を調査する.
- Ab3がヒト胃がん抗原に対するオリジナルのモノクローナル抗体 (Ab1) の結合特異性を複製できるかどうかを判断する.
- 腫瘍抗原に似た免疫応答を誘発することによって,がん治療におけるAb2の可能性を調査する.
主な方法:
- BALB/cのマウスとウサギを,特定のイディオタイプを標的としたヤギの抗イディオタイプ抗体 (Ab2) で予防接種する.
- モノクローナル・アンチ・アンチ・イディオタイプ抗体の生成と特徴づけ (Ab3).
- 結束性アッセイは,腫瘍抗原に対するAb1,Ab2,Ab3の特異性とアヴィディティを比較するものです.
主要な成果:
- 免疫化されたマウスから単一クローンAb3 (IgG1同型) が成功裏に生成されました.
- ネズミとウサギから派生したAb3は,同じ胃腸がん関連抗原を結合するAb1と同一の結合特異性と類似したアビデティを示した.
- Ab2は成功裏に抗原特異のAb3を誘導し,腫瘍抗原の"内部画像"を携えていることを示唆しました.
結論:
- 抗イディオタイプ抗体 (Ab2) は,元の抗体の結合特性を模倣する抗原特異の抗イディオタイプ抗体 (Ab3) の形成を誘導することができます.
- Ab2は,腫瘍に関連した抗原に対して免疫反応を誘発することによって,ワクチン候補としての可能性を実証しました.
- これらの発見は,がん患者の免疫反応を調節するために,抗イディオタイプ抗体の使用を支持する.
関連する概念動画
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity
Overview
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


